Precision BioSciences Investor Relations Material

Precision BioSciences Inc. is a U.S.-based biotechnology company focused on developing gene editing technologies. The company utilizes its proprietary ARCUS genome editing platform to research and develop treatments for genetic disorders and cancers. Its work spans cell and gene therapies, with applications in both in vivo and allogeneic CAR T-cell therapies. Precision BioSciences collaborates with academic institutions and pharmaceutical companies to advance its research and clinical programs. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.